Suppr超能文献

补充益生菌对妊娠期糖尿病患者遗传和代谢特征的影响:一项随机、双盲、安慰剂对照试验。

The Effects of Probiotic Supplementation on Genetic and Metabolic Profiles in Patients with Gestational Diabetes Mellitus: a Randomized, Double-Blind, Placebo-Controlled Trial.

机构信息

Department of Microbiology and Immunology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.

Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, I.R., Iran.

出版信息

Probiotics Antimicrob Proteins. 2019 Dec;11(4):1227-1235. doi: 10.1007/s12602-018-9490-z.

Abstract

This study was carried out to evaluate the effects of probiotic supplementation on genetic and metabolic profiles in patients with gestational diabetes mellitus (GDM) who were not on oral hypoglycemic agents. This randomized, double-blind, placebo-controlled clinical trial was conducted in 48 patients with GDM. Participants were randomly divided into two groups to intake either probiotic capsule containing Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, Lactobacillus fermentum (2 × 10 CFU/g each) (n = 24) or placebo (n = 24) for 6 weeks. Probiotic intake upregulated peroxisome proliferator-activated receptor gamma (P = 0.01), transforming growth factor beta (P = 0.002) and vascular endothelial growth factor (P = 0.006), and downregulated gene expression of tumor necrosis factor alpha (P = 0.03) in peripheral blood mononuclear cells of subjects with GDM. In addition, probiotic supplementation significantly decreased fasting plasma glucose (β, - 3.43 mg/dL; 95% CI, - 6.48, - 0.38; P = 0.02), serum insulin levels (β, - 2.29 μIU/mL; 95% CI, - 3.60, - 0.99; P = 0.001), and insulin resistance (β, - 0.67; 95% CI, - 1.05, - 0.29; P = 0.001) and significantly increased insulin sensitivity (β, 0.009; 95% CI, 0.004, 0.01; P = 0.001) compared with the placebo. Additionally, consuming probiotic significantly decreased triglycerides (P = 0.02), VLDL-cholesterol (P = 0.02), and total-/HDL-cholesterol ratio (P = 0.006) and significantly increased HDL-cholesterol levels (P = 0.03) compared with the placebo. Finally, probiotic administration led to a significant reduction in plasma malondialdehyde (P < 0.001), and a significant elevation in plasma nitric oxide (P = 0.01) and total antioxidant capacity (P = 0.01) was observed compared with the placebo. Overall, probiotic supplementation for 6 weeks to patients with GDM had beneficial effects on gene expression related to insulin and inflammation, glycemic control, few lipid profiles, inflammatory markers, and oxidative stress.

摘要

本研究旨在评估益生菌补充剂对未服用口服降糖药的妊娠期糖尿病(GDM)患者遗传和代谢谱的影响。这是一项随机、双盲、安慰剂对照的临床试验,共纳入了 48 例 GDM 患者。参与者被随机分为两组,分别摄入含有嗜酸乳杆菌、干酪乳杆菌、双歧杆菌、发酵乳杆菌(各 2×10 CFU/g)的益生菌胶囊(n=24)或安慰剂(n=24),持续 6 周。益生菌摄入可上调过氧化物酶体增殖物激活受体γ(P=0.01)、转化生长因子β(P=0.002)和血管内皮生长因子(P=0.006),并下调 GDM 患者外周血单个核细胞中肿瘤坏死因子α的基因表达(P=0.03)。此外,益生菌补充剂可显著降低空腹血糖(β,-3.43mg/dL;95%置信区间,-6.48,-0.38;P=0.02)、血清胰岛素水平(β,-2.29μIU/mL;95%置信区间,-3.60,-0.99;P=0.001)和胰岛素抵抗(β,-0.67;95%置信区间,-1.05,-0.29;P=0.001),并显著增加胰岛素敏感性(β,0.009;95%置信区间,0.004,0.01;P=0.001),与安慰剂相比。此外,与安慰剂相比,摄入益生菌可显著降低甘油三酯(P=0.02)、VLDL-胆固醇(P=0.02)和总胆固醇/HDL-胆固醇比值(P=0.006),并显著升高 HDL-胆固醇水平(P=0.03)。最后,与安慰剂相比,益生菌治疗可显著降低血浆丙二醛(P<0.001),并显著升高血浆一氧化氮(P=0.01)和总抗氧化能力(P=0.01)。总的来说,对 GDM 患者补充益生菌 6 周对与胰岛素和炎症相关的基因表达、血糖控制、少数血脂谱、炎症标志物和氧化应激有有益影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验